We are live on ! Find out more
BRNS

Barinthus Biotherapeutics
BRNS

15 hedge funds and large institutions have $22.2M invested in Barinthus Biotherapeutics in 2022 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

42% more capital invested

Capital invested by funds: $15.7M → $22.2M (+$6.57M)

36% more funds holding

Funds holding: 11 → 15 (+4)

0.3% more ownership

Funds ownership: 27.13% → 27.42% (+0.3%)

67% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 3

Holders
15
Holders Change
+4
Holders Change %
+36.36%
% of All Funds
0.24%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.03%
New
4
Increased
1
Reduced
3
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Baird Financial Group
Baird Financial Group
Wisconsin
+$235K
2
Citadel Advisors
Citadel Advisors
Florida
+$44.3K
3
TSS
Two Sigma Securities
New York
+$43.1K
4
Millennium Management
Millennium Management
New York
+$25.4K

Top Sellers

Rank Fund Capital Flow
1
IIM
Ipswich Investment Management
Massachusetts
-$5.35K
2
UBS Group
UBS Group
Switzerland
-$3.66K
3
Morgan Stanley
Morgan Stanley
New York
-$1.92K
Name Holding Trade Value Shares
Change 		Change in
Stake
MGIM
1
M&G Investment Management
United Kingdom
$10.4M – – –
AI
2
Alphabet Inc
California
$3.56M – – –
HH
3
HSG Holding
Hong Kong
$3.34M – – –
DF
4
DC Funds
Virginia
$1.51M – – –
LIP
5
Liontrust Investment Partners
United Kingdom
$1.43M – – –
BCM
6
BlueCrest Capital Management
Jersey
$1.28M – – –
JHU
7
Johns Hopkins University
Maryland
$254K – – –
Baird Financial Group
8
Baird Financial Group
Wisconsin
$217K +$235K +92,461 New
Millennium Management
9
Millennium Management
New York
$97K +$25.4K +9,967 +33%
IIM
10
Ipswich Investment Management
Massachusetts
$50.2K -$5.35K -2,100 -9%
Citadel Advisors
11
Citadel Advisors
Florida
$41.5K +$44.3K +17,383 New
TSS
12
Two Sigma Securities
New York
$39.8K +$43.1K +16,919 New
Morgan Stanley
13
Morgan Stanley
New York
$27.8K -$1.92K -753 -6%
UBS Group
14
UBS Group
Switzerland
$8.81K -$3.66K -1,437 -28%
NECFA
15
New England Capital Financial Advisors
Connecticut
$282 +$265 +104 New

BRNS Hedge Fund Activity: Q4 2022 in Review

15 of the 6,223 institutional investors tracked by Wall St. Rank reported a position in Barinthus Biotherapeutics (BRNS) for Q4 2022, worth a combined $22.2M — up 42% from $15.7M a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new BRNS positions and 0 closed out — a net gain of 4 holders — while 1 added to existing stakes and 3 trimmed.

The largest buyer was Baird Financial Group, opening a new position worth an estimated $235K. The largest seller was Ipswich Investment Management, cutting an estimated $5.35K.

  • 15 institutional investors held Barinthus Biotherapeutics (BRNS) as of Q4 2022, up from 11 in Q3 2022.
  • Funds reported $22.2M of Barinthus Biotherapeutics stock for Q4 2022, up 42% quarter-over-quarter.
  • 4 funds opened new Barinthus Biotherapeutics positions in Q4 2022 and 0 closed out, a net change of +4 holders.
  • The largest Barinthus Biotherapeutics buyer in Q4 2022 was Baird Financial Group, an estimated $235K added.
  • The largest Barinthus Biotherapeutics seller in Q4 2022 was Ipswich Investment Management, an estimated $5.35K sold.

Based on aggregated 13F filings for Q4 2022.